Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer

Inclusion Criteria: * only female participants are being studied * signed informed consent * patients with histologically proven or suspicious recurrent epithelial ovarian cancer (based on Response Evaluation Criteria in Solid Tumors (RECIST)- or CA-125 criteria) * Progression-free interval after completion of adjuvant platinum-based chemotherapy of 6 months or more. * Subjects with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, adenocarcinoma N.O.S. * Patients are eligible if the disease is deemed operable to equal or less than 1 cm at the completion of surgery. Exclusion Criteria: * mucinous Ovarian cancer * non-invasive Borderline tumor * subjects who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded. Prior radiation for localized cancer of the breast, head and neck, or skin are permitted, provided that it was completed more than 3 years prior to enrollment, and the subject remains free of recurrent or metastatic disease * subjects with active infection that requires parenteral antibiotics * patients with any underlying cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions, chronic or latent infectious diseases, immune deficiency, or history, which in the opinion of the investigator, places the patient at an unacceptable risk for participation in the study * patients with known platinum allergy * evidence of extensive intraperitoneal adhesions at the time of surgery, as determined by the operating surgeon